Previous 10 | Next 10 |
The following slide deck was published by Simulations Plus, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Simulations Plus, Inc. 2022 Q2 - Results - Earnings Call Presentation
Simulations Plus press release (NASDAQ:SLP): FQ2 GAAP EPS of $0.21 beats by $0.06. Revenue of $14.8M (+12.5% Y/Y) beats by $0.3M. Gross profit increased 17% to $12.0 million; gross margin was 81%. Adjusted EBITDA of $7.2 million, representing 48% of total revenue. For further details see: ...
Total revenue growth of 13%; Software revenue growth of 25%; Diluted Earnings Per Share (EPS) growth of 40% Board of Directors announces quarterly dividend of $0.06 per share Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation ...
Simulations Plus (NASDAQ:SLP) is scheduled to announce FQ2 earnings results on Wednesday, April 6th, after market close. The consensus EPS Estimate is $0.12 (-20.0% Y/Y) and the consensus Revenue Estimate is $14.5M (+10.3% Y/Y). Over the last 1 year, SLP has beaten EPS estimates 100% of the t...
CLIR, IRNT, LEVI, SLP For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Wednesday's close
SLP will partner with the University of Pittsburgh and its Liver-on-a-Chip platform Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has received ...
Attendees from 57 Countries Spend Two Days Focused on Advancing Model-Informed Drug Development Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, announced record-sett...
Conference Call to be on Wednesday, April 6, 2022, at 5:00 PM ET Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the second quarter of fiscal year 2022, the period ended February 28, 2022, after the close of the financial m...
Improving access to treatment in the lives of individuals and families affected by rare diseases Simulations Plus (Nasdaq: SLP) is celebrating 25 years in business and continuing the commitment to improve public health through innovative solutions with a $25,000 donation...
New functionality for transdermal products creates a state-of-the-art IVIVE methodology in combination with the GastroPlus TCAT platform Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnolog...
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...